Rafael Holdings, Inc. (RFL) company profile
Close on Nov 17, 2026Market cap $47.67MP/E –Yield –
About Rafael
Pharmaceutical Preparations, SIC 2834
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in early-stage and clinical healthcare and technology businesses. Its lead drug candidate, Trappsol Cyclo (remibetadex), targets Niemann-Pick Disease Type C. Through its subsidiaries and majority-owned portfolio entities, the company engages in liposomal cancer therapies via LipoMedix, orthopedic surgical instruments through Rafael Medical Devices, and product formulation technologies via Day Three Labs. It also retains legacy interests in cancer therapeutics and commercial real estate. Customers and commercial end users include healthcare providers, surgical specialists, diagnostic and pharmaceutical companies purchasing cyclodextrins, and third-party manufacturers utilizing proprietary ingredient technology.
The company's clinical research spans global clinical trial operations, having authorized Phase 3 study sites across 13 countries including the United States, United Kingdom, Israel, Germany, and Brazil. Rafael Holdings is headquartered in Newark, New Jersey, and retains an interest in a commercial building in Jerusalem, Israel.
Summary of the business section of Rafael's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rafael Holdings, Inc.
- Headquarters
- Newark, NJ
- Address
- 520 Broad Street 07120
- Phone
- (212) 658-1450
- Website
- rafaelholdings.com
- Employees
- 17, Jul 31, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- July 31
- Auditor
- CohnReznick LLP, Hartford, Connecticut
Stock & identifiers
- Ticker
- RFL
- Exchange
- NYSE
- Shares outstanding
- 52M, Oct 26, 2026
- Public float
- $37.20M, Jan 30, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1713863
- CUSIP
- 75062E106
- ISIN
- US75062E1064
- FIGI
- BBG00J3YYS92
- Share class FIGI
- BBG00J3YYSB9
- EIN
- 82-2296593
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Howard S. Jonas | Exec Chairman, CEO & President, Director | 15,042,008 |
| David Polinsky | Chief Financial Officer | 292,839 |
| Joshua M. Fine | Chief Operating Officer | 9,380 |
| William Conkling | Chief Executive Officer | 564,455 |
| John Goldberg | CHIEF MEDICAL OFFICER | 50,000 |
| Markus Sieger | Director | 219,710 |
| Mark N. Stein | Director | 50,845 |
| Michael J. Weiss | Director | 141,861 |
| Alan Grayson | Director | 6,562 |
| N. Scott Fine | Director | 335,348 |
| Stephen M. Greenberg | Director | 102,491 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Howard Jonas | $294.00K | $298.89K | $530.55K | $85 | – |
| FY2025 William Conkling | $592.91K | $611.63K | $530.55K | $85 | – |
| FY2024 | $859.30K | $658.22K | $649.20K | $74 | – |
| FY2023 | $751.95K | $685.32K | $406.69K | $99 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Howard Jonas Chairman of the Board, Chief Executive Officer (3) and Executive Chairman | $44.00K | – | $250.00K | – | $294.00K | -46% |
| William Conkling Chief Executive Officer (6) | $447.61K | – | $117.24K | $28.07K | $592.91K | -31% |
| John Goldberg Chief Medical Officer (11) | $427.30K | – | $97.70K | $8.75K | $533.75K | -30% |
| David Polinsky Chief Financial Officer (16) | $300.01K | $120.00K | $97.70K | $9.64K | $527.35K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“ur different businesses units is critical to our success . As of October 15, 2026, Rafael Holdings and its subsidiaries had 15 full-time and 2 part-time employees. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and i”
Corporate history
Events identified from SEC filings
See a number that looks wrong?